Onset of obstructive sleep apnea after initiation of psychotropic agents [8]

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 6, 2007, Pages 471-

  Yarlagadda, Atma R ^a   Brown, Anita B ^b   Clayton, Anita H ^c  

^a Clinical Associates of Tidewater   (United States)

^b CMHS   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; FLUOXETINE; LORAZEPAM;

ADULT; ANXIETY; CASE REPORT; DEPRESSION; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; LETTER; MALE; POSTTRAUMATIC STRESS DISORDER; SIDE EFFECT; SLEEP APNEA SYNDROME; WEIGHT GAIN;

EID: 37249029823     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v09n0611h     Document Type: Letter

References (4)

1. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
2. Carney RM, Howells WB, Freedland KE, et al. Depression and obstructive sleep apnea in patients with coronary heart disease. Psychosom Med 2006;68:443-448
3. Raeder MB, Bjelland I, Vollset SE, et al. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The Hordaland Health Study. J Clin Psychiatry 2007;67:1974-1982
4. Schroder CM, O'Hara R. Depression and obstructive sleep apnea (OSA). Ann Gen Psychiatry 2005;4:13